Current role of thalidomide in cancer treatment

被引：63

作者：

Thomas, DA ^{[1
]}

Kantarjian, HM ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

CURRENT OPINION IN ONCOLOGY | 2000年 / 12卷 / 06期

关键词：

D O I：

10.1097/00001622-200011000-00009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Thalidomide (Thalidomid, Celgene, Warren, NJ) is a putative anti-angiogenesis and immunomodulatory agent that has demonstrated activity in various dermatologic and rheumatologic conditions in addition to Crohn's disease. The biologic effects of thalidomide and the clinical trials conducted in solid tumors, hematologic malignancies, chronic graft-versus-host disease (GVHD), and cancer-related cachexia are reviewed. A summary of the preliminary results of ongoing clinical trials is presented, and the future directions of thalidomide research in the oncology are discussed. Curr Opin Oncol 2000, 12:564-573 (C) 2000 Lippincott Williams & Wilkins, Inc.

引用

页码：564 / 573

页数：10

共 95 条

[91] TUMOR ANGIOGENESIS - A NEW SIGNIFICANT AND INDEPENDENT PROGNOSTIC INDICATOR IN EARLY-STAGE BREAST-CARCINOMA [J].

WEIDNER, N ;

FOLKMAN, J ;

POZZA, F ;

BEVILACQUA, P ;

ALLRED, EN ;

MOORE, DH ;

MELI, S ;

GASPARINI, G .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (24) :1875-1887

[92] TUMOR ANGIOGENESIS AND METASTASIS - CORRELATION IN INVASIVE BREAST-CARCINOMA [J].

WEIDNER, N ;

SEMPLE, JP ;

WELCH, WR ;

FOLKMAN, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (01) :1-8

[93]

WEIDNER N, 1993, AM J PATHOL, V143, P401

[94]

YARCHOAN R, 1998, P 12 WORLD AIDS C

[95] STEPS™:: A comprehensive program for controlling and monitoring access to thalidomide [J].

Zeldis, JB ;

Williams, BA ;

Thomas, SD ;

Elsayed, ME .

CLINICAL THERAPEUTICS, 1999, 21 (02) :319-330

← 1 2 3 4 5 6 7 8 9 10 →